Summit Therapeutics PLC (SMMT) — Capital Reinvestment Ratio
Summit Therapeutics PLC (SMMT) has a Capital Reinvestment Ratio of 0.23x as of December 2022, meaning it reinvests 0% of its operating cash flow ($4.23 Million) in capital expenditures ($994.38K). See debt-free asset ratio of Summit Therapeutics PLC to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Summit Therapeutics PLC Capital Reinvestment Ratio (2004–2016)
This chart tracks Summit Therapeutics PLC's Capital Reinvestment Ratio across 2 annual periods. Check Summit Therapeutics PLC (SMMT) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Summit Therapeutics PLC (2004–2016)
Year-by-year Capital Reinvestment Ratio for Summit Therapeutics PLC from 2004 to 2016. For live market cap and broader valuation context, see SMMT market cap overview.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2016 | 0.01x | $15.18 Million | $110.00K | ▼ -96.9% |
| 2004 | 0.23x | $56.48K | $13.18K | — |